Activity of this pathway correlated with leukemia progression and therapy resistance [22, 23] and increase of eIF2α-P in primary Lin-CD34+ cells accompanied CML progression and enhanced their leukemogenic potential [22]. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.